Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
11
10
2019
medline:
18
9
2020
entrez:
11
10
2019
Statut:
ppublish
Résumé
Radioiodine-refractory thyroid cancers represent the main cause of thyroid cancer-related death. At present, targeted therapies with multikinase inhibitors represent a unique therapeutic tool, though they have limited benefit on patient survival and severe drug-associated adverse events. This review summarizes current treatment strategies for radioiodine-refractory thyroid cancer and focuses on novel approaches to redifferentiate thyroid cancer cells to restore responsiveness to radioiodine administration. We summarize and discuss recent clinical trial findings and early data from real-life experiences with multikinase-inhibiting drugs. Possible alternative strategies to traditional redifferentiation are also discussed. The current review focuses primarily on the major advancements in the knowledge of the pathophysiology of iodine transport and metabolism and the genetic and epigenetic alterations occurring in thyroid neoplasia as described using preclinical models. Results of clinical studies employing new compounds to induce thyroid cancer cell redifferentiation by acting against specific molecular targets are also discussed. Finally, we describe the current scenario emerging from such findings as well as future perspectives.
Identifiants
pubmed: 31599772
doi: 10.1097/CCO.0000000000000593
pii: 00001622-202001000-00004
doi:
Substances chimiques
Iodine Radioisotopes
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-19Références
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26:1–133.
Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91:2892–2899.
Durante C, Costante G, Filetti S. Differentiated thyroid carcinoma: defining new paradigms for postoperative management. Endocr Relat Cancer 2013; 20:R141–R154.
Jin Y, Van Nostrand D, Cheng L, et al. Radioiodine refractory differentiated thyroid cancer. Crit Rev Oncol Hematol 2018; 125:111–120.
Lamartina L, Durante C, Filetti S, et al. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab 2015; 100:1748–1761.
De la Vieja A, Santisteban P. Role of iodide metabolism in physiology and cancer. Endocr Relat Cancer 2018; 25:R225–R245.
Scott DA, Wang R, Kreman TM, et al. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Gen 1999; 21:440–443.
Devuyst O, Golstein PE, Sanches MV, et al. Expression of CFTR in human and bovine thyroid epithelium. Am J Physiol 1997; 272:C1299–C1308.
Twyffels L, Strickaert A, Virreira M, et al. Anoctamin-1/TMEM16A is the major apical iodide channel of the thyrocyte. Am J Physiol Cell Physiol 2014; 307:C1102–C1112.
Martín M, Geysels RC, Peyret V, et al. Implications of Na+/I− symporter transport to the plasma membrane for thyroid hormonogenesis and radioiodide therapy. J Endocr Soc 2019; 3:222–234.
Fernandez LP, Lopez-Marquez A, Santisteban P. Thyroid transcription factors in development, differentiation and disease. Nat Rev Endocrinol 2015; 11:29–42.
Arturi F, Russo D, Giuffrida D, et al. Sodium-iodide symporter (NIS) gene expression in lymph node metastases of papillary thyroid carcinomas. Eur J Endocrinol 2000; 143:623–627.
Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med 2016; 375:2307.
Tavares C, Coelho MJ, Eloy C, et al. NIS expression in thyroid tumors, relation with prognosis, clinicopathological and molecular features. Endocr Connect 2018; 7:78–90.
Phay JE, Ringel MD. Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr Relat Cancer 2013; 20:R307–R319.
Durante C, Puxeddu E, Ferretti E, et al. B-RAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92:2840–2843.
Feng F, Yehia L, Ni Y, et al. A nonpump function of sodium iodide symporter in thyroid cancer via cross-talk with PTEN signaling. Cancer Res 2018; 78:6121–6133.
Amit M, Na’ara S, Francis D, et al. Posttranslational regulation of radioactive iodine therapy response in papillary thyroid carcinoma. J Natl Cancer Inst 2017; 109:
Smith VE, Read ML, Turnell AS, et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci 2009; 122:3393–3402.
Massimino M, Tirrò E, Stella S, et al. Effect of combined epigenetic treatments and ectopic NIS expression on undifferentiated thyroid cancer cells. Anticancer Res 2018; 38:6653–6662.
Wächter S, Damanakis AI, Elxnat M, et al. Epigenetic modifications in thyroid cancer cells restore NIS and radio-iodine uptake and promote cell death. J Clin Med 2018; 7:
Celano M, Mio C, Sponziello M, et al. Targeting posttranslational histone modifications for the treatment of nonmedullary thyroid cancer. Mol Cell Endocrinol 2018; 469:38–47.
Riesco-Eizaguirre G, Wert-Lamas L, Perales-Paton J, et al. The miR 146b-3p/PAX8/NIS regulatory circuit modulates the differentiation phenotype and function of thyroid cells during carcinogenesis. Cancer Res 2015; 75:4119–4130.
Shen CT, Qiu ZL, Song HJ, et al. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(−) symporter in thyroid cancer by regulating MAPK signaling pathway. J Exp Clin Cancer Res 2016; 35:101.
Celano M, Rosignolo F, Maggisano V, et al. MicroRNAs as biomarkers in thyroid carcinoma. Int J Genom 2017; 2017:6496570.
Wang X, Huang S, Li X, et al. A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma. PLoS One 2018; 13:e0200290.
Rowe CW, Paul JW, Gedye C, et al. Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer 2017; 24:R191–R202.
So YK, Son YI, Baek CH, et al. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma. Ann Surg Oncol 2012; 19:990–995.
Bruno R, Ferretti E, Tosi E, et al. Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin. J Clin Endocrinol Metab 2005; 90:5692–5697.
D’Agostino M, Sponziello M, Puppin C, et al. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 2014; 52:121–131.
Aiello A, Pandini G, Frasca F, et al. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006; 147:4463–4475.
Nagarajah J, Le M, Knauf JA, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest 2016; 126:4119–4124.
Fröhlich E, Wahl R. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. Cancer Treat Rev 2014; 40:665–674.
Spitzweg C, Bible KC, Hofbauer LC, et al. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol 2014; 2:830–842.
Bulotta S, Celano M, Costante G, et al. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Endocrine 2016; 52:214e221.
Wächter S, Wunderlich A, Greene BH, et al. Selumetinib activity in thyroid cancer cells: modulation of sodium iodide symporter and associated miRNAs. Int J Mol Sci 2018; 19:
Zhang H, Chen D. Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. Thyroid Res 2018; 11:13.
Cheng L, Jin Y, Liu M, et al. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E. Oncotarget 2017; 8:19843–19854.
Puppin C, Passon N, Hershman JM, et al. Cooperative effects of SAHA and VPA on NIS gene expression and proliferation of thyroid cancer cells. J Mol Endocrinol 2012; 48:217–227.
Fu H, Cheng L, Jin Y, et al. MAPK inhibitors enhance HDAC inhibitor-induced redifferentiation in papillary thyroid cancer cells harboring BRAF V600E: an in vitro study. Mol Ther Oncolytics 2019; 12:235–245.
Gao X, Wu X, Zhang X, et al. Inhibition of BRD4 suppresses tumor growth and enhances iodine uptake in thyroid cancer. Biochem Biophys Res Commun 2016; 469:679–685.
Ferretti E, Tosi E, Po A, et al. Notch signaling is involved in expression of thyrocyte differentiation markers and is down-regulated in thyroid tumors. J Clin Endocrinol Metab 2008; 93:4080–4087.
Sponziello M, Verrienti A, Rosignolo F, et al. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. Endocrine 2015; 50:434–441.
Tesselaar MH, Crezee T, Swarts HG, et al. Digitalis-like compounds facilitate non-medullary thyroid cancer redifferentiation through intracellular Ca2+, FOS, and autophagy-dependent pathways. Mol Cancer Ther 2017; 16:169–181.
Brent GA, Kogai T. Cancer: novel target to enhance radioiodine uptake in thyroid cancer. Nat Rev Endocrinol 2013; 9:508–509.
Smith VE, Sharma N, Watkins RJ, et al. Manipulation of PBF/PTTG1IP phosphorylation status; a potential new therapeutic strategy for improving radioiodine uptake in thyroid and other tumors. J Clin Endocrinol Metab 2013; 98:2876–2886.
Guan H, Liang W, Xie Z, et al. Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine 2015; 48:566–574.
Li L, Lv B, Chen B, et al. Inhibition of miR-146b expression increases radioiodine-sensitivity in poorly differential thyroid carcinoma via positively regulating NIS expression. Biochem Biophys Res Commun 2015; 462:314–321.
Davies T, Latif R. Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies. Expert Opin Ther Targets 2015; 19:835–847.
Paolino D, Cosco D, Gaspari M, et al. Targeting the thyroid gland with thyroid stimulating hormone (TSH)-nanoliposomes. Biomaterials 2014; 35:7101–7109.
Gao XJ, Li AQ, Zhang X, et al. Thyroid-stimulating hormone (TSH)-armed polymer-lipid nanoparticles for the targeted delivery of cisplatin in thyroid cancers: therapeutic efficacy evaluation. RSC Adv 2015; 5:106413–106420.
Dotan I, Roche PJ, Paliouras M, et al. Engineering multiwalled carbon nanotube therapeutic bionanofluids to selectively target papillary thyroid cancer cells. PLoS One 2016; 11:e0149723.
Capdevila J, Newbold K, Licitra L, et al. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer. Cancer Treat Rev 2018; 69:164–176.
Thomas L, Lai SY, Dong W, et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014; 19:251–258.
Berdelou A, Borget I, Godbert Y, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 2018; 28:72–78.
Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16:1613–1623.
Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368:623–632.
Ho A. ASTRA: a phase III, randomized, placebo-controlled study evaluating complete remission rate (CRR) with short-course selumetinib plus adjuvant radioactive iodine (RAI) in patients (pts) with differentiated thyroid cancer (DTC). Thyroid 2018; 28: (Suppl 1):
Rothenberg SM, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib-response. Clin Cancer Res 2015; 21:5640–5641.
Boland A, Magnon C, Filetti S, et al. Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid 2002; 12:19–26.
Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J Clin Endocrinol Metab 2019; 104:1417–1428.
Jaber T, Waguespack SG, Cabanillas ME, et al. Targeted therapy in advanced thyroid cancer to resensitize tumors to radioactive iodine. J Clin Endocrinol Metab 2018; 103:3698–3705.
Leboulleux S, Dupuy C, Lacroix L, et al. Redifferentiation of a BRAF K601E-mutated poorly differentiated thyroid cancer patient with dabrafenib and trametinib treatment. Thyroid 2019; 29:735–742.
Coelho SM, Corbo R, Buescu A, et al. Retinoic acid in patients with radioiodine nonresponsive thyroid carcinoma. J Endocrinol Invest 2004; 27:334–339.
Groener JB, Gelen D, Mogler C, et al. BRAF V600E and retinoic acid in radioiodine-refractory papillary thyroid cancer. Horm Metab Res 2019; 51:69–75.
Nilubol N, Merkel R, Yang L, et al. A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin. Clin Endocrinol (Oxf) 2017; 86:128–133.
Xing M. Entering an era of precision management of thyroid cancer. Endocrinol Metab Clin North Am 2019; 48:xvii–xviii.
van der Tuin K, Ventayol Garcia M, Corver WE, et al. Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma. Eur J Endocrinol 2019; 180:235–241.
Lombardo GE, Maggisano V, Celano M, et al. AntihTERT siRNA-loaded nanoparticles block the growth of anaplastic thyroid cancer xenograft. Mol Cancer Ther 2018; 17:1187–1195.
Allegri L, Baldan F, Mio C, et al. Effects of BP-14, a novel cyclin-dependent kinases inhibitor, on anaplastic thyroid cancer cells. Oncol Rep 2016; 35:2413–2418.
Antonello ZA, Hsu N, Bhasin M, et al. Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E. Oncotarget 2017; 8:84743–84760.
Min IM, Shevlin E, Vedvyas Y, et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors. Clin Cancer Res 2017; 23:7569–7583.
Fesnak A, Lin C, Siegel DL, et al. CAR-T cell therapies from the transfusion medicine perspective. Transfus Med Rev 2016; 30:139–145.
Guo Y, Wang Y, Han W. Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects. J Immunol Res 2016; 2016:3850839.
Jerkovich F, García Falcone MG, Pitoia F. The experience of an endocrinology division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer. Endocrine 2019; 64:632–638.